Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to AU$1.25, the stock trades at a trailing P/E ratio of 27.9x. Average trailing P/E is 36x in the Life Sciences industry globally. Total returns to shareholders of 128% over the past three years. Reported Earnings • Mar 03
First half 2026 earnings released: EPS: AU$0.023 (vs AU$0.017 in 1H 2025) First half 2026 results: EPS: AU$0.023 (up from AU$0.017 in 1H 2025). Revenue: AU$8.27m (up 25% from 1H 2025). Net income: AU$1.14m (up 36% from 1H 2025). Profit margin: 14% (up from 13% in 1H 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 18% per year. New Risk • Feb 28
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 114% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks High level of debt (114% net debt to equity). Market cap is less than US$100m (AU$58.8m market cap, or US$41.9m). Board Change • Jan 13
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Board Change • Dec 11
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Valuation Update With 7 Day Price Move • Oct 27
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to AU$1.30, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 36x in the Life Sciences industry globally. Total returns to shareholders of 125% over the past three years. Board Change • Sep 18
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Aug 22
Full year 2025 earnings released: EPS: AU$0.039 (vs AU$0.038 in FY 2024) Full year 2025 results: EPS: AU$0.039 (up from AU$0.038 in FY 2024). Revenue: AU$14.1m (up 12% from FY 2024). Net income: AU$1.88m (up 2.4% from FY 2024). Profit margin: 13% (down from 15% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Aankondiging • Aug 18
Cryosite Limited, Annual General Meeting, Oct 16, 2025 Cryosite Limited, Annual General Meeting, Oct 16, 2025. Location: at the thomson geer offices, at level 23, rialto south tower, 525 collins street, melbourne vic 3004 Australia Recent Insider Transactions • Jul 02
Non-Executive Chairman recently bought AU$56k worth of stock On the 27th of June, Mark Kerr bought around 75k shares on-market at roughly AU$0.74 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Mark's only on-market trade for the last 12 months. Board Change • Jun 23
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Board Change • Mar 17
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Non-Executive Chairman Mark Kerr is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Feb 24
First half 2025 earnings released: EPS: AU$0.017 (vs AU$0.017 in 1H 2024) First half 2025 results: EPS: AU$0.017 (in line with 1H 2024). Revenue: AU$6.64m (up 3.7% from 1H 2024). Net income: AU$838.0k (flat on 1H 2024). Profit margin: 13% (in line with 1H 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 24% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Nov 22
Cryosite Limited Announces Resignation of Michael Austin as Joint Company Secretary Cryosite Limited announced that Mr. Michael Austin has resigned as Joint Company Secretary, effective 22 November 2024. Mr. Hamish George of Bio101 Financial Advisory Pty Ltd. remains as Company Secretary and is responsible for communications with the ASX in relation to Listing Rule matters under ASX Listing Rule 12.6. Aankondiging • Oct 21
Cryosite Limited, Annual General Meeting, Nov 22, 2024 Cryosite Limited, Annual General Meeting, Nov 22, 2024. Location: boardroom, level 2 90 william st, melbourne,vic, 3000., melbourne, Australia Aankondiging • Sep 20
Cryosite Limited Announces Company Secretary Changes Cryosite Limited announced that Hamish George and Michael Austin of Bio101 Financial Advisory Pty Ltd. (Bio101) have been appointed Joint Company Secretaries of the Company. The appointment follows the resignation of Mr. Dray Andrea as Company Secretary, effective 20 September 2024. The Board would like to thank Mr. Andrea for his service in the role of Company Secretary. Declared Dividend • Aug 22
Final dividend of AU$0.02 announced Shareholders will receive a dividend of AU$0.02. Ex-date: 6th September 2024 Payment date: 10th October 2024 Dividend yield will be 8.8%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is well covered by both earnings (46% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 14% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Aug 21
Full year 2024 earnings released: EPS: AU$0.038 (vs AU$0.029 in FY 2023) Full year 2024 results: EPS: AU$0.038 (up from AU$0.029 in FY 2023). Revenue: AU$12.6m (up 5.7% from FY 2023). Net income: AU$1.84m (up 31% from FY 2023). Profit margin: 15% (up from 12% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year and the company’s share price has also increased by 22% per year. Buy Or Sell Opportunity • Jul 26
Now 20% undervalued Over the last 90 days, the stock has risen 14% to AU$0.97. The fair value is estimated to be AU$1.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.5% over the last 3 years. Earnings per share has grown by 29%. New Risk • Jun 26
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: AU$8.2m This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks Significant insider selling over the past 3 months (AU$8.2m sold). Market cap is less than US$100m (AU$56.1m market cap, or US$37.5m). Aankondiging • Jun 25
Cryosite Limited Announces Retirement of Andrew Kroger from the Board of Directors Cryosite Limited announced that Andrew Kroger has retired from the board of directors (Board) effective from June 25, 2024. Valuation Update With 7 Day Price Move • May 24
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to AU$1.05, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 32x in the Life Sciences industry globally. Total returns to shareholders of 238% over the past three years. Recent Insider Transactions • Apr 27
Non Executive Director recently sold AU$830k worth of stock On the 23rd of April, Andrew Kroger sold around 1m shares on-market at roughly AU$0.83 per share. This transaction amounted to 7.3% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Aankondiging • Feb 22
Cryosite Limited Announces Board Changes Cryosite Limited announced the appointment of Mr. Andrew Kerr as a Director of the Company. Mr. John Hogg will step down as Managing Director and continue in his current executive position as CEO of Cryosite. Andrew is an experienced financial services professional in both the Australian and international markets. Andrew is a qualified Certified Practising Accountant (CPA) and a graduate of the Australian Institute of Company Directors (GAICD) course. Through his roles at Bank of America Merrill Lynch and Macquarie Bank, Andrew has obtained strong sustainability and ESG credentials which will greatly complement the Board. Upcoming Dividend • Feb 14
Upcoming dividend of AU$0.05 per share at 2.2% yield Eligible shareholders must have bought the stock before 21 February 2024. Payment date: 29 February 2024. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Australian dividend payers (6.5%). Higher than average of industry peers (0.5%). Board Change • Dec 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Chairman Mark Kerr was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Dec 08
Cryosite Limited Announces Director Changes Cryosite Limited announced the appointment of Mr. Mark Kerr, as a new Director and Chairman. Mr. John Hogg, CEO of Cryosite will also join the Board as the Managing Director. The only variation to Mr. Hogg's employment agreement is to reflect his new office with the Company. The company announced the retirement from the Board of Directors of Steven Waller, Nicola Swift and Luis Antonio. The Board thanks the three retiring directors for their outstanding contribution to the Company over a number of years. The retiring directors have contributed substantial hours beyond what was expected to ensure the success of the Company going forward. Aankondiging • Oct 02
Cryosite Limited, Annual General Meeting, Nov 23, 2023 Cryosite Limited, Annual General Meeting, Nov 23, 2023, at 11:01 AUS Eastern Standard Time. Location: The offices of Cryosite, 13A Ferndell St, South Granville New South Wales Australia Upcoming Dividend • Aug 31
Upcoming dividend of AU$0.015 per share at 1.5% yield Eligible shareholders must have bought the stock before 07 September 2023. Payment date: 06 October 2023. Payout ratio is a comfortable 52% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Australian dividend payers (7.0%). Higher than average of industry peers (0.5%). Aankondiging • Aug 25
Cryosite Limited Announces Dividend for the Twelve Months Ended June 30, 2023, Payable on October 6, 2023 Cryosite Limited announced dividend of AUD 0.01500000 per share for the twelve months ended June 30, 2023. Record date is September 8, 2023. Ex-date is September 7, 2023. Payment date is October 6, 2023. Reported Earnings • Feb 24
First half 2023 earnings released: EPS: AU$0.014 (vs AU$0.016 in 1H 2022) First half 2023 results: EPS: AU$0.014 (down from AU$0.016 in 1H 2022). Revenue: AU$5.72m (down 1.7% from 1H 2022). Net income: AU$678.7k (down 13% from 1H 2022). Profit margin: 12% (down from 13% in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 150% per year, which means it is well ahead of earnings. Aankondiging • Jan 20
Cryosite Limited Announces Change of Company Secretary Cryosite Limited announces the resignation of Kim Bradley-Ware and the appointment of Dray Andrea as Company Secretary, both effective January 18, 2023. Recent Insider Transactions • Jan 18
Insider recently bought AU$481k worth of stock On the 13th of January, Mark Kerr bought around 650k shares on-market at roughly AU$0.74 per share. This transaction amounted to 39% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth AU$582k. Insiders have collectively bought AU$2.6m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Dec 26
Insider recently bought AU$582k worth of stock On the 19th of December, Mark Kerr bought around 885k shares on-market at roughly AU$0.66 per share. This transaction amounted to 79% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$2.1m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Oct 14
Insider recently bought AU$447k worth of stock On the 11th of October, Mark Kerr bought around 600k shares on-market at roughly AU$0.74 per share. This transaction amounted to 63% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$1.6m more in shares than they have sold in the last 12 months. Aankondiging • Sep 21
Cryosite Limited, Annual General Meeting, Nov 17, 2022 Cryosite Limited, Annual General Meeting, Nov 17, 2022, at 10:00 E. Australia Standard Time. Location: at the offices of Stone & Chalk, Level 4, 11 York Street, Sydney NSW 2000 Sydney Nsw 2000 Australia Upcoming Dividend • Sep 08
Upcoming dividend of AU$0.01 per share Eligible shareholders must have bought the stock before 15 September 2022. Payment date: 14 October 2022. Trailing yield: 1.4%. Lower than top quartile of Australian dividend payers (6.6%). Higher than average of industry peers (0.4%). Aankondiging • Aug 26
Cryosite Limited Announces Ordinary Dividend for the Year Ended June 30, 2022, Payable on October 14, 2022 Cryosite Limited announced ordinary dividend of AUD 0.01000000 for the year ended June 30, 2022. Record Date is September 16, 2022. Ex Date is September 15, 2022. Payment Date is October 14, 2022. Reported Earnings • Aug 26
Full year 2022 earnings released: EPS: AU$0.028 (vs AU$0.014 in FY 2021) Full year 2022 results: EPS: AU$0.028 (up from AU$0.014 in FY 2021). Revenue: AU$11.8m (up 17% from FY 2021). Net income: AU$1.36m (up 109% from FY 2021). Profit margin: 12% (up from 6.5% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 136% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Nicola Swift was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Mar 03
Non Executive Director recently bought AU$321k worth of stock On the 28th of February, Andrew Kroger bought around 716k shares on-market at roughly AU$0.45 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$931k more in shares than they have sold in the last 12 months. Reported Earnings • Feb 24
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: EPS: AU$0.016 (up from AU$0.006 in 1H 2021). Revenue: AU$5.82m (up 19% from 1H 2021). Net income: AU$782.4k (up 175% from 1H 2021). Profit margin: 13% (up from 5.8% in 1H 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 119% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions Derivative • Sep 09
Key Executive exercised options to buy AU$546k worth of stock. On the 6th of September, Bryan Dulhunty exercised options to buy 1m shares at a strike price of around AU$0.06, costing a total of AU$78k. This transaction amounted to 4,333% of their direct individual holding at the time of the trade. Bryan currently holds less than 1% of total shares outstanding. Company insiders have collectively bought AU$687k more than they sold, via options and on-market transactions, in the last 12 months. Reported Earnings • Aug 26
Full year 2021 earnings released: EPS AU$0.014 (vs AU$0.032 in FY 2020) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: AU$10.1m (up 12% from FY 2020). Net income: AU$652.6k (down 56% from FY 2020). Profit margin: 6.5% (down from 17% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Jun 11
Non Executive Director recently bought AU$170k worth of stock On the 8th of June, Andrew Kroger bought around 473k shares on-market at roughly AU$0.36 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$173k more in shares than they have sold in the last 12 months. Is New 90 Day High Low • Feb 17
New 90-day low: AU$0.21 The company is down 25% from its price of AU$0.28 on 18 November 2020. The Australian market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 11% over the same period. Is New 90 Day High Low • Dec 21
New 90-day high: AU$0.36 The company is up 59% from its price of AU$0.23 on 22 September 2020. The Australian market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 12
New 90-day high: AU$0.30 The company is up 76% from its price of AU$0.17 on 14 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 12% over the same period. Is New 90 Day High Low • Oct 08
New 90-day high: AU$0.24 The company is up 71% from its price of AU$0.14 on 10 July 2020. The Australian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 2.0% over the same period. Is New 90 Day High Low • Sep 18
New 90-day high: AU$0.21 The company is up 65% from its price of AU$0.13 on 18 June 2020. The Australian market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 11% over the same period. 
